Quoin Pharmaceuticals Secures Key U.S. Patent for Netherton Syndrome Treatment
Event summary
- Quoin Pharmaceuticals received a Notice of Allowance from the USPTO for a patent covering its combination treatment for Netherton Syndrome.
- The patent covers a method using a topical serine protease inhibitor with an anti-inflammatory agent, specifically for patients with SPINK5 mutations.
- QRX003 (QYLEKI™), Quoin’s investigational treatment, holds Orphan Drug, Rare Pediatric Disease, and Fast Track designations in the U.S., and Orphan Drug Designation in the EU and Japan.
- The patent is expected to be granted following payment of the issue fee, strengthening Quoin’s intellectual property position for its Netherton Syndrome program.
The big picture
Quoin Pharmaceuticals’ patent approval strengthens its position in the rare disease space, particularly for Netherton Syndrome, where there are currently no approved treatments. The company’s strategic focus on securing intellectual property and regulatory designations underscores its long-term commercialization strategy. This move aligns with broader industry trends of targeting orphan diseases with high unmet medical needs, potentially offering significant market opportunities.
What we're watching
- Regulatory Milestones
- The pace at which Quoin advances its Phase 3 study and NDA filing for QRX003, with initiation expected in the second half of 2026.
- Commercial Strategy
- Whether Quoin can successfully self-commercialize QRX003 in key markets like the U.S., Japan, and Western Europe if approved.
- Pipeline Expansion
- How Quoin leverages its intellectual property to expand into other rare and orphan skin diseases beyond Netherton Syndrome.